Palbociclib*
-
API Product :
Palbociclib*
-
CEP :
-
-
WCC :
-
-
Therapeutic Use :
Antineoplastics
-
Originator :
PFIZER
-
CAS No. :
571190-30-2
-
Trade Name. :
IBRANCE
-
Molecular Weight :
447.533 g/mol
-
Molecular Formula :
C24H29N7O2
Application
Palbociclib is used to treat a certain type of breast cancer in women. It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells.
General Description
Palbociclib (codenamed PD-0332991, trade name Ibrance) is a drug for the treatment of ER-positive and HER2-negative breast cancer developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.[1][2] Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy by any organization.